West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 6:20 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 6:20 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Reasons to Add Patterson Companies (PDCO) to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study
by Zacks Equity Research
Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 8.21% and 0.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 9.90% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Worried About Market Froth? Buy These 3 Dividend Stocks
by Ethan Feller
If you are concerned about the massive rally in tech leading to sharp corrections, then taking profits or adding other positions may be a prudent move
West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
5 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.
S&P 500 Reclaims 4,500 Level: 5 Best Stocks in ETF
by Sweta Killa
The S&P 500 Index reached 4,500 for the first time in more than 15 months We have highlighted five stocks in ETF from different sectors that have gained more than 50% this year and have a Zacks Rank #1 (Strong Buy) or #2 (Buy).
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL
by Zacks Equity Research
Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.
Veeva (VEEV) Falls Nearly 3% on Morgan Stanley Downgrade
by Zacks Equity Research
Veeva's (VEEV) shares lose nearly 3% after Morgan Stanley downgrades the stock to underweight, citing potential revenue loss from Salesforce's entry into the Life Sciences customer relationship management market.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Cardinal Health (CAH) to Build Distribution Center in Greenville
by Zacks Equity Research
Cardinal Health's (CAH) new facility will be its largest at-Home Solutions distribution center that will support business growth by providing new space and automation.
CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Revvity (RVTY) Launches Single Solution for Drug Development
by Zacks Equity Research
Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.
Penumbra (PEN) Launches New Technology for Blood Clot Removal
by Zacks Equity Research
Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.